Slide 1: Third Quarter 2021 Earnings Presentation
ANGIODYNAMICS Third Quarter 2021 Earnings Presentation March 30, 2021 1
Slide 2: Forward-Looking Statement
Forward-Looking Statement Notice Regarding Forward-LookingStatements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements regarding AngioDynamics’ expected future financial position, results of operations, ca
Slide 3: Corporate Developments – Q3 Highlights
Corporate Developments – Q3 Highlights • Continued focused investment in our 3 key technology platforms: Auryon, AngioVac & NanoKnife • Procedural volumes negatively impacted in January and first half of February • Began to rebound in the second half of February • AngioVac and Auryon procedure volum
Slide 4: Third Quarter FY2021 Highlights
Third Quarter FY2021 Highlights Financial Performance Product Family Sales Growth Over Prior Year Periods YOY Vascular Interventions and Therapies Q3 FY2021 YTD FY2021 Q3 FY2021 Q3 FY2020 $ in thousands (except per share data) Change AngioVac® 27% 31% Revenue $71,182 $69,780 2.0% Auryon NA* NA* Thro
Slide 5: Third Quarter FY2021 Results (unaudited)
Third Quarter FY2021 Results (unaudited) $ in thousands (except per share data) Q3 FY2021 Q3 FY2020 Change YTD FY2021 YTD FY2020 Change Revenue $71,182 $69,780 2.0% $214,168 $205,825 4.1% Vascular Interventions and Therapies $33,251 $30,552 8.8% $97,008 $90,616 7.1% Vascular Access $24,813 $24,642 0
Slide 6: GAAP to Non-GAAP Reconciliation
GAAP to Non-GAAP Reconciliation 6
Slide 7: Reconciliation of GAAP to Non-GAAP Net Income and EPS; Net Loss to Adjusted EBITDA
Reconciliation of GAAP to Non- Reconciliation of Net Loss to GAAP Net Income and EPS Adjusted EBITDA (in thousands, except per share data) (in thousands) (1) Includes costs related to merger and acquisition activities, restructurings, and unusual items, including asset impairments and write-offs, ce
Slide 8: AngioDynamics
i>) angiodynamics